Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial - Tolaney, S M; Tarantino, P; Graham, N (Lancet Oncol, 2023)